Figure-1 (Figure 1)
Praxbind Injection
Product Images NDC 0597-0197
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Praxbind (NDC 0597-0197). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Boehringer Ingelheim Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure-2 (Figure 2)
Figure-3 (Figure 3)
Figure-4 (Figure 4)
This is a graph showing the time-course of unbound dabigatran levels in a group of healthy subjects after administration of Idarucizumab or Placebo. The various time points, in hours, and related levels of unbound dabigatran are specified on the graph. The lower limit of quantification is 1ng/mL.*
Figure-5 (Figure 5)
Figure-6 (Figure 6)
The text describes a figure that shows the change in ECT from baseline in patients exposed to Dabigatran, with 487 participants. The figure shows a graph with ECT values on the Y-axis and different time intervals on the X-axis. There are different line plots with data points and percentiles represented in the graph. It is not possible to understand the graph completely without looking at it, but this is the basic information that can be obtained from the text.*
Figure-7 (Figure 7)
This is a graph showing the change in aPTT (activated partial thromboplastin time) from baseline in 486 patients exposed to the drug Dabigatran. The graph displays the values at baseline, at 1 hour, 2 hours, 4 hours, 12 hours, and 24 hours post-Idarucizumab. The y-axis ranges from 130 to 140. There are additional details regarding percentiles and upper limits of normal.*
Praxbind-label (Label 019705)
Praxbind® (idarucizumab) Injection is used for intravenous treatment and comes in 2.5g/50 mL single-dose vials. The complete dose of 5g necessitates administering two vials. The product should be kept at 2°C-8°C, and the package should be held away from light until it is time to use it. Please see the package insert for complete prescribing information about dosage and administration. Discard unused portions. No additional information is available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
